Information message

In order to see all the search results and access content, you must log in. Please use the Log-in button at the top of the page.

Displaying 157 - 168 of 565
Liver Tumours
EASL Studio Podcast S6 E9: Therapy hierarchy in HCC: A new kid on the block

EASL Studio Podcast S6 E9: Therapy hierarchy in HCC: A new kid on the block

Podcasts
View

EASL Studio S6 E9: Therapy hierarchy in HCC: A new kid on the block

Description

This episode centres around an article recently published in the Journal of Hepatology, presenting a new treatment algorithm positioned as an evolution of the BCLC system and aimed at addressing its limitations in the staging and therapy hierarchy for HCC. This discussion covers the implications of this fresh approach in the management of HCC patients, challenging the standard paradigm.

ha

The novel framework includes the concepts of multi-parametric and converse therapeutic hierarchy.

 

BCLC

BCLC staging and treatment strategy in 2022.

Faculty

  • Bruno Sangro (Moderator)
  • Umberto Cillo (Faculty) 
  • Helen Reeves (Faculty)
  • María Reig (Faculty)

This EASL Studio is supported by AstraZeneca. EASL has received no input from AstraZeneca with regards to the content of this programme.

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments
EASL Membership
Off
Liver Tumours
EASL Molecular Tumour Board on intrahepatic cholangiocarcinoma - 23 May 2023

EASL Molecular Tumour Board on intrahepatic cholangiocarcinoma - 23 May 2023

EASL Molecular Tumour Boards
View
Liver Tumours
EASL Molecular Tumour Board on intrahepatic cholangiocarcinoma - 12 March 2024

EASL Molecular Tumour Board on intrahepatic cholangiocarcinoma - 12 March 2024

EASL Molecular Tumour Boards
View

EASL Studio S6 E5: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?

Description

The definition of cACLD is now strongly linked to care and research outcomes such as non invasive diagnosis, reversibility and prevention of decompensation. Thus, what space is left for the use of the old term cirrhosis in clinical practice and research?

Faculty

  • Paolo Angeli (Moderator)
  • Guadalupe Garcia-Tsao (Faculty)
  • Valérie Paradis (Faculty)
  • Thomas Reiberger (Faculty)

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments
EASL Membership
Off
Cirrhosis & Complications
EASL Studio Podcast S6 E5: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?

EASL Studio Podcast S6 E5: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?

Podcasts
View

EASL Studio S6 E8: Is there a role for measuring blood ammonia in patients with cirrhosis?

Description

In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs.

Faculty

  • Debbie Shawcross (Moderator)
  • Rajiv Jalan (Faculty)
  • Sara Montagnese (Faculty)
  • Elliot Tapper (Faculty)

This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments
EASL Membership
Off
Cirrhosis & Complications
EASL Studio Podcast S6 E8:  Is there a role for measuring blood ammonia in patients with cirrhosis?

EASL Studio Podcast S6 E8: Is there a role for measuring blood ammonia in patients with cirrhosis?

Podcasts
View
General Hepatology
EASL Studio Podcast S6 E7: The impact of policy measure in preventing liver diseases: The Hepahealth II study

EASL Studio Podcast S6 E7: The impact of policy measure in preventing liver diseases: The Hepahealth II study

Podcasts
View
Liver Tumours
EASL Studio Podcast S6 E4: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyond

EASL Studio Podcast S6 E4: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyond

Podcasts
View
Immune-Mediated and Cholestatic Diseases
Quiz: A 40-year-old male patient has been previously diagnosed with PSC by MRCP and has no concomitant IBD

Quiz: A 40-year-old male patient has been previously diagnosed with PSC by MRCP and has no concomitant IBD

Quiz
View

EASL Studio S6 E7: The impact of policy measure in preventing liver diseases: The Hepahealth II study

Description

This episode treats of the Hepahealth II study, which aimed at estimating the impact of policy interventions targeting alcohol and obesity on the incidence of chronic liver disease and primary liver cancer in three European countries. Join our experts in their discussion of this study and of its conclusions.

Faculty

  • Patrizia Burra (Moderator)
  • Maria Buti (Faculty)
  • Peter Jepsen (Faculty)
  • Shira Zelber-Sagi (Faculty)

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments
EASL Membership
Off